Mr. Todd Shapiro reports

RED LIGHT HOLLAND ENGAGES KALA BIO'S RESEARGENCY.AI PLATFORM TO SUPPORT CLINICAL DEVELOPMENT OF FILAMENT HEALTH'S PATENTED PEX010 BOTANICAL PSILOCYBIN DRUG CANDIDATE

Red Light Holland Corp. has engaged Kala Bio Inc.'s Researgency.ai agentic artificial intelligence platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modelling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament's business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic rationale

The engagement of the Researgency.ai platform represents a key element of Red Light's strategy to integrate advanced AI-driven research capabilities as it looks to expand Filament's regulated psychedelic drug development platform. By deploying Kala Bio's purpose-built AI agents, Red Light also intends to accelerate and enhance research planning, scenario simulation and protocol optimization processes associated with advancing PEX010 through Filament's clinical development pipeline.

PEX010 is Filament's patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with an exclusive worldwide distribution/development licence owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical research and development workflows. The platform enables autonomous research loops capable of generating, simulating and optimizing study scenarios at scale, compressing timelines, and expanding the number of viable options considered before execution. The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development.

Management commentary

"As we move to integrate Filament's exceptional clinical assets and intellectual property, engaging Kala Bio's Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation," said Todd Shapiro, chief executive officer and director of Red Light Holland. "PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world. By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs and make smarter, faster decisions across PEX010's extensive clinical program."

"Filament's focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development," said Ben Lightburn, chief executive officer of Filament Health. "With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio's Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve."

"Red Light's decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address," said Avi Minkowitz, chief executive officer of Kala Bio. "Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference. We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world."

The company further announces that it has engaged Solidaire Investments Inc., a merchant bank, based in Calgary, Alta., to provide capital market advisory and investor relations consulting services. The agreement is effective immediately for a one-month term, during which the company will pay Solidaire a fee of $20,000. Solidaire is principally owned and operated by Mohamed Elsaghir, a shareholder of the company.

About Red Light Holland Corp.

Red Light Holland is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centred on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. The company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Dutch legal market and mushroom home grow kits offered through business-to-business and DTC channels in compliance with applicable laws. Red Light has entered into a definitive arrangement agreement to acquire Filament Health, which is expected to expand the company's drug development platform with good manufacturing practice manufacturing capabilities, comprehensive Health Canada licensing, Food and Drug Administration-authorized clinical programs, and a portfolio of 76 issued patents.

We seek Safe Harbor.